Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
Jörg Mahlich,1,2 Rosarin Sruamsiri1,3 1Health Economics, Janssen Pharmaceutical KK, Tokyo, Japan; 2Düsseldorf Institute for Competition Economics (DICE), University of Düsseldorf, Düsseldorf, Germany; 3Center of Pharmaceutical Outcomes Research, Department of Pha...
Main Authors: | Mahlich J, Sruamsiri R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-08-01
|
Series: | Patient Preference and Adherence |
Subjects: | |
Online Access: | https://www.dovepress.com/persistence-with-biologic-agents-for-the-treatment-of-rheumatoid-arthr-peer-reviewed-article-PPA |
Similar Items
-
A Real-World Claims Database Study Assessing Long-Term Persistence with Golimumab Treatment in Patients with Rheumatoid Arthritis in Japan
by: Masahiko Miyashiro, et al.
Published: (2023-02-01) -
Preference for shared decision-making in Japanese patients with rheumatoid arthritis
by: Jörg Mahlich, et al.
Published: (2017-01-01) -
Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New “Preference Fit” Framework for Treatment Assessment
by: Jörg Mahlich, et al.
Published: (2019-05-01) -
The underrated prevalence of depression in Japanese patients with rheumatoid arthritis - evidence from a Nationwide survey in Japan
by: Rosarin Sruamsiri, et al.
Published: (2017-11-01) -
Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
by: Jean-Hugues Salmon, et al.
Published: (2020-05-01)